|
Company:
|
AYTU BIOPHARMA, INC (AYTU)
|
|
Form Type:
|
S-8
|
|
Filing Date:
|
7/2/2015
|
|
CIK:
|
0001385818
|
|
Address:
|
373 INVERNESS PARKWAY
SUITE 206
|
|
City, State, Zip:
|
ENGLEWOOD, Colorado 80112
|
|
Telephone:
|
(720) 437-6580
|
|
Fiscal Year:
|
06/30
|
|
|
|
|
|
Last Trade
|
Last Trade:
$0.29
|
Change:
-0.002 (-0.62%)
|
Trade Time:
Aug 12
|
Market Cap:
$17.54M
|
|
|
|
|
|
|
Description of Business
|
|
We are a commercial-stage specialty pharmaceutical company focused on
commercializing novel products that address needs in both prescription and
consumer health categories. Through our prescription business, and following our
recent merger with Neos Therapeutics, Inc. ("Neos"), which closed on March 19,
2021, we market a portfolio of prescription products addressing large markets
with a focus on general pediatric conditions, attention deficit/hyperactivity
disorder ("ADHD") and insomnia. We also market a portfolio of consumer health
products also addressing large categories through our consumer health
subsidiary, acquired in February 2020. Our goal is to become a leading specialty
pharmaceutical company focused on large prescription and consumer health
categories while building a late-stage development pipeline addressing
significant medical needs.
|
|
|
|